FDA Clears EZFuse System, Heralding New Era in Endoscopic Surgery

GOSSELIES, Belgium – March 17, 2026 – Belgian medical device innovator Endo Tools Therapeutics (ETT) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation endomina® EZFuse system. The clearance paves the way for immediate U.S. commercialization of a technology poised to significantly accelerate and simplify minimally invasive gastrointestinal procedures.

The endomina® EZFuse system is designed for the endoscopic placement of sutures and the approximation of soft tissue within the GI tract. ETT states the device’s redesigned, intuitive platform can reduce total procedure time by up to 50%, a claim that, if borne out in widespread clinical practice, could represent a major leap in operational efficiency for hospitals and ambulatory surgery centers.

"The EZFuse system clearance marks an important milestone in the continued evolution of the endomina system and introduces a number of improvements to simplify workflow and to enhance the physician experience," said Alexandre Chau, CEO of Endo Tools Therapeutics, in a company statement. "We are excited that the new system is making it easier for physicians to adopt and integrate our device into their practice."

The Endoscopic Efficiency Revolution

At the core of the EZFuse system's promise is a fundamental redesign aimed at streamlining the complex task of suturing inside the gastrointestinal tract. Traditional endoscopic procedures can be limited by the dexterity and functionality of tools passed through a long, flexible endoscope. ETT’s technology mounts onto a standard endoscope, providing a stable platform with articulating arms that emulate the triangulation of laparoscopic surgery, but without the need for external incisions.

The next-generation EZFuse system builds on this foundation with a single-movement suturing mechanism. This innovation is engineered to eliminate multiple steps from the suturing process, creating a more direct and predictable workflow. For clinical teams, this translates to reduced mental and physical fatigue during long procedures, a shorter learning curve for new users, and greater procedural consistency.

This focus on efficiency extends beyond the operating room. By potentially cutting procedure times in half, the EZFuse system could allow hospitals and outpatient surgery centers to optimize resource utilization, improve scheduling flexibility, and expand overall procedural capacity. In an era of increasing pressure on healthcare systems to do more with less, such advancements are critical for managing patient backlogs and improving access to care.

Paving the Way for Broader Minimally Invasive Care

The FDA clearance represents more than just a new tool; it signifies another step in the broader shift away from open surgery toward incisionless, minimally invasive interventions. For patients, the benefits of this trend are profound: less postoperative pain, shorter hospital stays, faster recovery times, and a lower risk of complications like surgical site infections.

While the EZFuse system is cleared in the U.S. for general soft tissue approximation in the GI tract, its predecessor has already established a significant track record in Europe and parts of the Middle East. There, the endomina platform is CE-marked and has been used in over 1,500 endoscopic gastroplasty procedures for the treatment of obesity. Clinical trials in Europe have demonstrated its effectiveness, with one randomized controlled trial showing patients achieved an average excess weight loss of 45.1% at 12 months, significantly outperforming lifestyle modifications alone.

Furthermore, ETT is sponsoring the ESTIME trial in France, investigating if weight loss induced by the procedure can lead to the remission of type 2 diabetes. While these specific indications for obesity and diabetes are not yet part of the U.S. clearance, the robust clinical data from Europe underscores the platform's potential and provides a foundation of trust as it enters the American market. The technology enables surgeons to perform complex tissue apposition and closure tasks entirely through a natural orifice, opening doors for a wider range of therapeutic endoscopic procedures.

Entering a Competitive U.S. MedTech Arena

With its FDA clearance, Endo Tools Therapeutics enters the highly competitive and lucrative U.S. endoluminal suturing market. The U.S. segment alone was valued at approximately $27.4 million in 2024 and is projected to grow at a rapid compound annual growth rate (CAGR) of 16.6% through 2034, fueled by the rising prevalence of GI disorders and the demand for less invasive treatments.

ETT will face established giants in the space. Boston Scientific, particularly after its acquisition of Apollo Endosurgery, is a dominant force with its widely adopted OverStitch and OverStitch Sx Endoscopic Suturing Systems. These devices are mainstays in procedures like endoscopic sleeve gastroplasty (ESG) and are backed by extensive clinical use. Other key competitors include Medtronic with its Endo Stitch device and Olympus with its SutuArt system.

To carve out a market share, ETT will rely on the EZFuse system's key differentiators: speed and simplicity. The company's leadership is confident that these advantages will drive adoption.

"With the FDA clearance of the next generation endomina® EZFuse system, we are reinforcing our commitment to make advanced endoscopic procedures faster, simpler, and more accessible to physicians while improving efficiencies for hospitals and ambulatory centers," noted Denis Gestin, Chairman of the Board at Endo Tools Therapeutics. "This milestone positions the company for accelerated growth and physician adoption in the U.S."

Strategy for Growth and Overcoming Hurdles

ETT has announced plans for immediate commercialization in the U.S., a strategy supported by an experienced leadership team. The recent hiring of Kevin Krose, a veteran of commercial expansion at Ambu, to lead its commercial efforts signals a clear intent for aggressive market penetration. The company's approach will likely mirror its previous U.S. launch, which involved a phased rollout and a strong emphasis on "best-in-class training" to ensure physicians are proficient and comfortable with the new technology.

However, the path to widespread adoption is not without obstacles. The high initial cost of advanced endoscopic systems can be a significant barrier for healthcare facilities, especially smaller ones with constrained budgets. Furthermore, mastering new endoscopic suturing devices requires a dedicated training investment and navigating a learning curve, even for experienced gastroenterologists.

Reimbursement also presents a complex landscape. While many endoscopic procedures have defined payment codes, novel technologies often must initially rely on unlisted procedure codes, creating uncertainty for providers regarding financial viability. ETT's success will depend on its ability to demonstrate not only clinical efficacy but also a clear economic value proposition to hospital administrators and payors, a strategy it has successfully pursued in Europe with programs like the "Forfait Innovation" in France. As the endomina® EZFuse system begins its journey in the U.S., the medical community will be watching closely to see if its promise of speed and simplicity can reshape the practice of therapeutic endoscopy.